#3047
Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1
Introduction:
An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Iyer A
Authors:
Iyer A,
Vriens J,
Dogan-Oruç F,
van Koetsveld P,
Hofland L,
Keywords:
β-arrestin 1,
CRISPR-Cas9,
BON-1,
knock-out,
SSTR,
SSA,
Pan-NET,
#2999
Aberrant Tryptophan Metabolism in Stromal Cells Is Associated with Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours
Introduction:
Increased levels of serotonin secretion are associated with mesenteric fibrosis (MF) in small intestinal neuroendocrine tumors (SI-NETs). However, only a proportion of patients with increased serotonin production will develop mesenteric fibrosis.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Blazevic A
Authors:
Blazevic A,
Iyer A,
Van Velthuysen M,
Hofland J,
Franssen G,
Keywords:
Small-intestinal neuroendocrine tumors,
mesenteric fibrosis,
serotonin,
tryptophan metabolism,
proteomics,
#2995
Prediction of Symptomatic Mesenteric Mass in Patients with Small Intestinal Neuroendocrine Tumors Using a CT Radiomics Approach
Introduction:
A mesenteric mass surrounded by fibrosis is a hallmark feature of small intestinal neuroendocrine tumors (SI-NETs) that can induce severe abdominal complications. To improve clinical outcome, there is a need for personalized treatment strategies based on accurate prediction of development of abdominal complications.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Blazevic A
Authors:
Blazevic A,
Starman M,
Brabander T,
Hofland J,
Franssen G,
Keywords:
Small-intestinal neuroendocrine tumors,
mesenteric mass,
mesenteric fibrosis,
radiomics,
CT scan,
#2283
Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors
Introduction:
Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Vandamme T
Authors:
Vandamme T,
Beyens M,
Van Camp G,
Boons G,
Hofland L,
Keywords:
pancreatic neuroendocrine tumors,
PNET,
genetics,
tumor heterogeneity,
hotspot mutations,
#2095
Progression of Mesenteric Metastasis in Small Intestinal Neuroendocrine Tumors
Introduction:
A metastatic mesenteric mass is a hallmark of small intestinal neuroendocrine tumours (SI-NETs). However, little is known about the development of a SI-NET associated mesenteric mass over time.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Blazevic A
Authors:
Blazevic A,
Feelders R,
Hofland J,
Franssen G,
Van Velthuysen M,
Keywords:
Small intestinal neuroendocrine tumor,
Mesenteric metastasis,
Radiology,
Peptide receptor radionuclide therapy,
